Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals
William Borden
Advertisement
Articles by William Borden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Great Repricing: How Pharma Must Evolve for Three Diverging Payer Economies
2
Trade & Channel Strategies 2025: Inside Pharma’s Turning Point
3
Pharma Pulse: Amgen's Uplizna Secures CD19 Approval for Myasthenia Gravis, as Asthma Biologic Switches Highlight Efficacy Expectations Gap
4
Working with the Middle
5
